I-SPY COVID Trial Suggests No Clinical Benefit from Addition of IC14 to Treatment of Critically Ill Patients with COVID-19
![](https://www.quantumleaphealth.org/wp-content/uploads/2024/05/header-proposal-submission-1024x510.jpeg)
Today Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, announced that the IC14 arm of the trial has been terminated. This decision was due to the high probability that IC14 would not have a large impact on either shortening time to recovery or mortality in critically ill patients with COVID-19.